Walgreens (NASDAQ: WBA) to Pay $106.8 Million to Settle US Prescription Billing Fraud Charges
Walgreens Boots Alliance (NASDAQ: WBA) agreed to pay $106.8 million to settle charges it fraudulently billed the U.S. government for […]
Healthcare
Eli Lilly (NYSE: LLY) Invests $1.8 Billion to Expand Production of Key Drugs in Ireland
Eli Lilly (NYSE: LLY) is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely
Eli Lilly (NYSE: LLY) Invests $1.8 Billion to Expand Production of Key Drugs in Ireland Read More »
GSK (NYSE: GSK) Advances mRNA Flu Vaccine to Late-Stage Trials
On Thursday, GSK (NYSE: GSK), the British drugmaker, announced positive results from a mid-stage trial of its seasonal influenza vaccine
GSK (NYSE: GSK) Advances mRNA Flu Vaccine to Late-Stage Trials Read More »
Weight-Loss Market to See 16 New Drugs by 2029: Report
The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business
Weight-Loss Market to See 16 New Drugs by 2029: Report Read More »
Teva and Walgreens Settle with Baltimore Ahead of Scheduled Opioid Trial
On Tuesday, Baltimore said that it has settled with Walgreens (NASDAQ: WBA) over claims that the pharmacy operator fueled opioid
Teva and Walgreens Settle with Baltimore Ahead of Scheduled Opioid Trial Read More »
Teva (NYSE: TEVA) Faces EU Antitrust Fine for Disparaging Rival Multiple Sclerosis Medicine: Reuters
BRUSSELS – Teva (NYSE: TEVA), the world’s largest generic drugmaker, will be hit with an EU antitrust fine in the
AstraZeneca (NASDAQ: AZN) Stock Dips on Lung Cancer Drug Trial Setback
AstraZeneca (NASDAQ: AZN) shares fell in the pre-market trading Tuesday after results from the company’s lung cancer trials showed that
AstraZeneca (NASDAQ: AZN) Stock Dips on Lung Cancer Drug Trial Setback Read More »
AstraZeneca Says Lung Cancer Drug Trial Shows No Significant Improvement in Overall Survival
LONDON – Detailed results from one of AstraZeneca’s (NASDAQ: AZN) key lung cancer trials released on Monday showed that its
MBX Biosciences Eyes $482.5M Valuation for US IPO
On Monday, MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including obesity, said it was
MBX Biosciences Eyes $482.5M Valuation for US IPO Read More »